TY - JOUR T1 - Glucose-lactate metabolic cooperation in cancer: insights from a spatial mathematical model and implications for targeted therapy JF - bioRxiv DO - 10.1101/008839 SP - 008839 AU - Jessica B. McGillen AU - Catherine J. Kelly AU - Alicia Martíez-González AU - Natasha K. Martin AU - Eamonn A. Gaffney AU - Philip K. Maini AU - Vıctor M. Pérez-García Y1 - 2014/01/01 UR - http://biorxiv.org/content/early/2014/09/04/008839.abstract N2 - A recent hypothesis has proposed a glucose-lactate metabolic symbiosis between adjacent hypoxic and oxygenated regions of a developing tumour, and proposed a treatment strategy to target this symbiosis. However, in vivo experimental support remains inconclusive. Here we develop a minimal spatial mathematical model of glucose-lactate metabolism to examine, in principle, whether metabolic symbiosis is plausible in human tumours, and to assess the potential impact of inhibiting it. We find that symbiosis is a robust feature of our model system—although on the length scale at which oxygen supply is diffusion-limited, its occurrence requires very high cellular metabolic activity—and that necrosis in the tumour core is reduced in the presence of symbiosis. Upon simulating therapeutic inhibition of lactate uptake, we predict that targeted treatment increases the extent of tissue oxygenation without increasing core necrosis. The oxygenation effect is correlated strongly with the extent of wildtype hypoxia and only weakly with wildtype symbiotic behaviour, and therefore may be promising for radiosensitisation of hypoxic, lactate-consuming tumours even if they do not exhibit a spatially well-defined symbiosis. Finally, we conduct a set of in vitro experiments on the U87 glioblastoma cell line to facilitate preliminary speculation as to where highly malignant tumours might fall in our parameter space, and find that these experiments suggest a weakly symbiotic regime for U87 cells, which raises the new question of what relationship exists between symbiosis—if indeed it occurs in vivo—and tumour malignancy. ER -